Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2…
<!-- Name:DistributionId Value:8808649 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
AFM13
Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed…
100% objective response rate and improvement in the rate of complete responses (CR) from 38% to 62% after a second cycle in 13 patients treated at the recommended phase 2 dose…
Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd…
AFM28 effectively induces depletion of leukemic cells in patient bone marrow samples and demonstrates the anticipated good safety profile and pharmacologic activity in cynomolgus…
Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive…
For the 13 patients treated at the recommended phase 2 dose (RP2D) the response rate after one cycle of treatment remains at 100% with a 38.5% complete response (CR) rate; one additional…
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of…
100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108…